15 terminated. 15 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 1 | Terminated 1 |
Follow Liver Failure: new trials by email Literature Review of Liver Failure trials Research Report on Liver Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites | Phase 2 | Terminated | Genfit | 15 | 2023-07-02 | 2026-07-23 |
| Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP) - Acetaminophen, Drug Overdose | Phase 2 | Terminated | Richard Dart, MD, PhD | 29 | 2022-09-12 | 2025-11-25 |
| Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy AXA1665, Placebo - Hepatic Encephalopathy | Phase 2 | Terminated | Axcella Health, Inc | 12 | 2021-06-29 | 2022-07-27 |
| Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy RBX7455, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver | Phase 2 | Terminated | Ochsner Health System | 5 | 2021-03-01 | 2023-10-03 |
| TAK-242 in Patients With Acute Alcoholic Hepatitis TAK-242, Placebo - Acute-On-Chronic Liver Failure | Phase 2 | Terminated | Akaza Bioscience Ltd | 4 | 2020-11-12 | 2026-10-14 |
| Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) HepaStem, Placebo - Acute on Chronic Liver Failure | Phase 2 | Terminated | Cellaion SA | 133 | 2020-01-21 | 2024-05-22 |
| Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure allo-APZ2-ACLF - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Terminated | RHEACELL GmbH & Co. KG | 5 | 2019-03-22 | 2021-11-17 |
| Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) ELAD - Acute Liver Failure, Fulminant Hepatic Failure | Phase 2 | Terminated | Vital Therapies, Inc. | 8 | 2014-10-01 | 2019-02-12 |
| Terlipressin Administration in Patients Undergoing Major Liver Resection Terlipressin, Placebo - Liver Resection, Liver Failure | Phase 2 | Terminated | Insel Gruppe AG, University Hospital Bern | 150 | 2013-11-01 | 2018-03-29 |
| Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF IDN-6556, Placebo - Acute on Chronic Hepatic Failure, Acute Liver Failure | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 23 | 2013-09-01 | 2016-04-11 |
| Quantitative Liver Function Tests Using Cholates Cholates - End Stage Liver Disease | Phase 2 | Terminated | Baylor Research Institute | 103 | 2011-06-23 | 2026-02-12 |
| Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning Silibinin - Amatoxin Poisoning, Amanita Poisoning | Phase 2 | Terminated | Mylan Specialty, LP | 148 | 2009-11-10 | 2022-04-07 |
| Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose) - Hepatic Encephalopathy | Phase 2 | Terminated | Amgen | 1 | 2007-12-01 | 2024-12-17 |
| Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents TIPS created with 8 or 10 mm covered stent - Cirrhosis | Phase 2 | Terminated | University of Roma La Sapienza | 44 | 2006-01-01 | 2009-01-09 |
Acute-On-Chronic Liver Failure (5) · Fibrosis (5) · Hepatic Encephalopathy (5) · Liver Cirrhosis (3) · End Stage Liver Disease (2) · Liver Failure, Acute (2) · Ascites (1) · Brain Diseases (1) · Chemical and Drug Induced Liver Injury (1) · Drug Overdose (1) · Hepatitis, Alcoholic (1) · Hypertension, Portal (1) · Kidney Diseases (1) · Liver Diseases (1)
Digestive System Diseases (15) · Hepatic Insufficiency (15) · Liver Diseases (14) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Brain Diseases, Metabolic (5) · Central Nervous System Diseases (5) · Liver Failure, Acute (5) · Metabolic Diseases (5) · Nervous System Diseases (5) · Nutritional and Metabolic Diseases (5) · Brain Diseases (4) · Chemically-Induced Disorders (3) · Fibrosis (2)
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · 4-methylpiperazine-2,6-dione (1) · Cholates (1) · Control Groups (1) · Glucose (1) · Silybin (1) · Sodium Benzoate (1) · Terlipressin (1) · ammonul (1) · ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (1) · phenylacetic acid (1)
Genfit (2) · Akaza Bioscience Ltd (1) · Amgen (1) · Axcella Health, Inc (1) · Baylor Research Institute (1) · Cellaion SA (1) · Conatus Pharmaceuticals Inc. (1) · Insel Gruppe AG, University Hospital Bern (1) · Mylan Specialty, LP (1) · Ochsner Health System (1) · RHEACELL GmbH & Co. KG (1) · Richard Dart, MD, PhD (1) · University of Roma La Sapienza (1) · Vital Therapies, Inc. (1)
United States (10) · Italy (4) · France (3) · Germany (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Hungary (2) · Poland (2) · Austria (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Estonia (1) · Georgia (1)
Andres Duarte-Rojo, M.D. (1) · Angel Alsina, MD (1) · David J Reich, MD (1) · Guido Beldi, Professor Dr. med. (1) · James Trotter, MD (1) · Jan Stange, MD, Ph.D. (1) · Juan Gallegos-Orozco, MD (1) · Julia Garcia-Diaz, MD (1) · Julie Thompson, MD (1) · Kalyan R Bhamidimarri, MD (1) · Lance Stein, MD (1) · Lewis W Teperman, MD (1) · Linda S Sher, MD (1)
PMID 31680011, PMID 33011075, PMID 37681263
2025 (1)